Clik here to view.
Diagnosis of Myelofibrosis
Individuals diagnosed with myelofibrosis often have no symptoms. An enlarged spleen or an abnormal blood count may be noticed at a routine check up. Once a diagnosis is suspected additional tests or...
View ArticleClik here to view.
Management of Myelofibrosis that Progresses to Acute Myeloid Leukemia
In some patients with myelofibrosis, the condition progresses to a type of leukemia known as acute myeloid leukemia (AML). Information about the management of AML is available here....
View ArticleMPN Clinical Trial Highlights
Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. Future progress in the treatment of myeloproliferative neoplasms (MPNs) will result from the continued...
View ArticleYear in Review: Myeloproliferative Neoplasms
Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms,...
View ArticleMPN Research Foundation Launches CancerConnect Social Media Platform
Austin TX/Sun Valley ID– With the launch of the CancerConnect online community, the MPN Research Foundation (MPNRF) now offers a specialized social network for individuals affected by...
View ArticleJakafi Significantly Improves Long-Term Outcomes in Myelofibrosis
The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual...
View ArticleAbout PCROWD, Dana-Farber’s tissue-banking study for patients with...
PCROWD (“Precursor CROWDsourcing”) – a tissue banking and clinical information study and repository – is an indispensable component of the blood cancer research pipeline. The main objective of PCROWD...
View ArticleMyeloproliferative Neoplasms Greatly Affect Patient Quality of Life
According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis....
View ArticleInterferon No Better Than Hydroxyurea and Associated with Worse Side Effects...
The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the...
View Article5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis
An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for...
View ArticleWhen Good Cells Go Bad
By Kari Bohlke, ScD Cancer. The word has taken on a meaning that extends beyond the medical definition. Cancer is deadly; it is dangerous; it means bad news. But when we hear the words, “You have...
View ArticleYear in Review: Myeloproliferative Neoplasms
Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms,...
View ArticleMPN Research Foundation Launches CancerConnect Social Media Platform
Austin TX/Sun Valley ID– With the launch of the CancerConnect online community, the MPN Research Foundation (MPNRF) now offers a […] The post MPN Research Foundation Launches CancerConnect Social Media...
View ArticleJakafi Significantly Improves Long-Term Outcomes in Myelofibrosis
The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented […] The post Jakafi...
View ArticleMyeloproliferative Neoplasms Greatly Affect Patient Quality of Life
According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health […] The post Myeloproliferative Neoplasms Greatly Affect...
View ArticleInterferon No Better Than Hydroxyurea and Associated with Worse Side Effects...
The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used […] The post Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects...
View Article5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis
An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term […] The post 5-Year Survival Improved with Early Use of...
View ArticleCTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
CTI BioPharma Corp. announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) […] The post CTI BioPharma Announces Removal Of Full Clinical Hold...
View ArticlePV Reporter Launches CancerConnect Social Media Platform
PV Reporter Launches CancerConnect Social Media Platform Ketchum/Sun Valley ID– With the launch of the CancerConnect online community, PV Reporter […] The post PV Reporter Launches CancerConnect Social...
View Article
